Chargement en cours...
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in patients with non-Val30Met transthyretin (TTR) amyloidosis. Twenty-one patients with eight different non-Val30Met mutations received 20 mg QD of tafamidis meglumine for 12 month...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer US
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3838581/ https://ncbi.nlm.nih.gov/pubmed/24101373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12265-013-9512-x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|